서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 33 of 33

Issue DateTitle / Author(s) / CitationFileAltmetrics
2006-12
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

Lee, Ju-Hee; Park, Jung-Hyun; Jung, Yeonjoo; Kim, Jee-Hyun; Jong, Hyun-Soon; Kim, Tae-You; Bang, Yung-Jue

Molecular Cancer Therapeutics, Vol.5 No.12, pp.3085-3095

DOI
2008-07
Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study
DOI
2009-08
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
DOI
2010-12
Combination Chemotherapy with S-1 and Platinum in Advanced Hepatocellular Carcinoma
2011-07
Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib
DOI
2012-03
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells
DOI
2012-07
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
DOI
2012-10
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
DOI
2012-11
Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: Preliminary results of a prospective study
DOI
2013-08
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer

Lee, Eunyoung; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog

Journal of Thoracic Oncology, Vol.8 No.8, pp.1069-1074

DOI
2013-09
How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
view fileDOI
2013-09
Survival Outcomes of Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy: Association with Dynamic Contrast-enhanced MR Imaging with Computer-aided Evaluation
DOI
2014-08
ALK Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization
DOI
2014-09
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
DOI
2014-11
A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
view fileDOI
2015-08
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
DOI
2015-12
Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer
DOI
2016-01
Observer variability in RECIST-based tumour burden measurements: A meta-analysis

Yoon, Soon Ho; Kim, Kyung Won; Goo, Jin Mo; Kim, Dong-Wan; Hahn, Seo Kyung

European Journal of Cancer, Vol.53, pp.5-15

DOI
2016-07
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial
DOI
2017-03
Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer
DOI
2017-09
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
view fileDOI
2017-11
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
DOI
2018-07
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
DOI
2018-07
Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol
DOI
2018-07
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial
DOI
2018-08
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
DOI
2018-08
Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity
DOI
2018-09
Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials
DOI
2018-10
Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibit ROS1/TRK/ALK solvent-front mutations
DOI
2020-03
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
DOI
2021-12
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
DOI
2022-03
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
DOI
2024-02
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types
DOI
1